Key facts
- This page summarizes Sukumar Nagendran's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2024, 16:42.
Sukumar Nagendran - 02 Jan 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)
- Reporting relationship
- President and Head of R&D, Director
- Issuer ticker
- TSHA
- Reported as of
- 02 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2024, 16:42:30 UTC
- Prior SEC filing
- 18 Dec 2023
- Next SEC filing
- 13 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kamran Alam, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sukumar Nagendran filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 04 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSHA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +863,617
- Change %
- +2523%
- Price
- $0.000000
- Shares after
- 897,843
- Date
- 02 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TSHA
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +863,617
- Change %
- Price
- $0.000000
- Shares after
- 863,617
- Date
- 02 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 863,617
- Exercise price
- $1.71
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date.
Footnote F2
25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.